• "Groundbreaking Malaria Vaccines Offer Hope in Africa's Fight Against the Deadly Disease"

  • Feb 23 2025
  • Length: 3 mins
  • Podcast

"Groundbreaking Malaria Vaccines Offer Hope in Africa's Fight Against the Deadly Disease"

Listen for free

View show details

  • Summary

  • In the ongoing battle against malaria, a disease that continues to devastate communities, particularly in sub-Saharan Africa, recent developments have brought both hope and challenges to the forefront.

    Nigeria, which bears the world's highest malaria burden, has recently launched a significant initiative with the roll-out of the R21/Matrix-M malaria vaccine. As of January 2025, the vaccine has been integrated into the routine immunisation schedules in Kebbi and Bayelsa states, areas with the highest malaria incidence in the country. This rollout, supported by Gavi, the Vaccine Alliance, UNICEF, and the World Health Organization (WHO), marks a crucial step in protecting children from this deadly disease. The vaccine, administered in a four-dose series, has already seen impressive turnout, with over 100 women bringing their children to vaccination centers each week[1].

    The R21/Matrix-M vaccine, along with the RTS,S vaccine, has been endorsed by the WHO for its efficacy in preventing malaria in children. Both vaccines have demonstrated significant reductions in malaria cases and hospitalizations for severe malaria. Data from pilot projects in Kenya, Ghana, and Malawi show a 13% reduction in all-cause mortality and a 22% drop in hospitalizations for severe clinical malaria among eligible children[1][3].

    In parallel to these vaccination efforts, new research is advancing the fight against malaria. Ocean Biomedical has received significant funding from the National Institutes of Health (NIH) to develop a novel malaria vaccine. Led by Dr. Jonathan Kurtis, the research focuses on a unique protein called glutamic acid-rich protein (GARP) found on the surface of malaria-infected red blood cells. Children who naturally resist severe malaria have been found to develop antibodies against GARP, paving the way for a potentially transformative vaccine. With FDA guidance on lipid-encapsulated vaccines, Ocean Biomedical is on track to initiate human trials as early as the fourth quarter of 2025[2].

    Despite these advancements, the fight against malaria remains complex. The disease has seen a stagnation in decline since 2015, partly due to mosquitoes developing resistance to primary insecticides and the parasite becoming resistant to treatment drugs. Additionally, the emergence of a new mosquito species, Anopheles stephensi, in East Africa has posed a threat to urban populations. Funding for malaria research has also hit its lowest recorded level, further complicating efforts[4].

    However, the introduction of these vaccines and ongoing research offer a beacon of hope. The WHO recommends the use of malaria vaccines in areas of moderate and high transmission, prioritizing children living in endemic regions. With concerted efforts and resources, these vaccines could significantly reduce the global malaria burden, saving thousands of lives, especially among children under five who are most vulnerable to the disease[3].
    Show More Show Less
Show More Show Less

What listeners say about "Groundbreaking Malaria Vaccines Offer Hope in Africa's Fight Against the Deadly Disease"

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.co.uk reviews

Amazon reviews
No Reviews are Available